Caseware UK (AP4) 2022.0.179 2022.0.179 2023-12-31149393472023-12-31truefalse12023-06-15false0 14939347 2023-06-14 14939347 2023-06-15 2023-12-31 14939347 2022-06-15 2023-06-14 14939347 2023-12-31 14939347 1 2023-06-15 2023-12-31 14939347 d:Director1 2023-06-15 2023-12-31 14939347 c:CurrentFinancialInstruments 2023-12-31 14939347 c:CurrentFinancialInstruments c:WithinOneYear 2023-12-31 14939347 c:ShareCapital 2023-12-31 14939347 c:RetainedEarningsAccumulatedLosses 2023-06-15 2023-12-31 14939347 c:RetainedEarningsAccumulatedLosses 2023-12-31 14939347 d:OrdinaryShareClass1 2023-06-15 2023-12-31 14939347 d:OrdinaryShareClass1 2023-12-31 14939347 d:FRS102 2023-06-15 2023-12-31 14939347 d:Audited 2023-06-15 2023-12-31 14939347 d:FullAccounts 2023-06-15 2023-12-31 14939347 d:PrivateLimitedCompanyLtd 2023-06-15 2023-12-31 14939347 d:SmallCompaniesRegimeForAccounts 2023-06-15 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure



















Aurobac Therapeutics UK Limited

Registered number: 14939347
Annual report
For the period ended 31 December 2023

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
REGISTERED NUMBER: 14939347

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

2023
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
 5 
227,379

Cash at bank and in hand
 6 
71,027

  
298,406

Creditors: amounts falling due within one year
 7 
(286,858)

Net current assets
  
 
 
11,548

Total assets less current liabilities
  
11,548

  

Net assets
  
11,548


Capital and reserves
  

Called up share capital 
 8 
1,000

Profit and loss account
 9 
10,548

Total equity
  
11,548


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




F M-C S Sejourne
Director

Date: 2 April 2024

The notes on pages 2 to 7 form part of these financial statements.
- 1 -

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

1.


General information

Aurobac Therapeutics UK Limited is a private company limited by shares and incorporated in England and Wales. Its registered number is 14939347. The address of its registered office is 30 Old Bailey, London, EC4M 7AU. The principal place of business is Flat 1, Ingleside, 39 Valley Drive, Harrogate, HG2 0JH.
The principal activity of the company is the research and development in biotechnology.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The financial statements have been presented in Pound Sterling as this is the currency of the primary economic environment in which the company operates and is rounded to the nearest pound.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements are prepared on a going concern basis. The Company remains assured of the financial support by the parent company. The Director has received confirmation that the parent company will continue to support the Company and provide it with adequate funds when necessary to enable it to meet its debts as they fall due in the foreseeable future. On this basis, the Director considers it appropriate to prepare the financial statements on a going concern basis.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentation currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

All other foreign exchange gains and losses are presented in the Statement of Comprehensive Income within 'administrative expenses'.

- 2 -

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.4

Turnover

Turnover arises from cost recharges made to the parent company with a mark up. 

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

- 3 -

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

  
2.11

Financial instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable.


3.


Judgements in applying accounting policies and key sources of estimation uncertainty

In applying the Company’s accounting policies, the Director is required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The Director's judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.
Bonus accrual
The Company operates an annual bonus plans for its employees. An expense is recognised in the profit and loss account when the Company has a legal or constructive obligation to make payments under the plans as a result of past events and a reliable estimate of the obligation can be made.


4.


Employees

The average monthly number of employees, excluding the director, during the period was 1.
The director was not remunerated by the company.

- 4 -

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

5.


Debtors

2023
£


Amounts owed by group undertakings
226,145

Prepayments and accrued income
1,234

227,379


Amounts owed by group undertakings which relate to trading transactions are unsecured, interest free and repayable on demand.


6.


Cash and cash equivalents

2023
£

Cash at bank and in hand
71,027

71,027



7.


Creditors: Amounts falling due within one year

2023
£

Trade creditors
186

Amounts owed to group undertakings
196,606

Corporation tax
3,699

Other taxation and social security
11,093

Accruals and deferred income
75,274

286,858


Amounts owed to group undertakings are unsecured, incur interest at a rate of 6% per annum and are repayable on demand.

- 5 -

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

8.


Share capital

2023
£
Allotted, called up and fully paid


1,000 ordinary shares of £1 each
1,000


1,000 shares were issued at par value on 15 June 2023.
The company has one class of ordinary shares; the share has attached to it full voting, dividend and capital distribution rights.


9.


Reserves

Profit and loss account

This reserve includes the current period profits and losses.


10.


Pension commitments

The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £4,200. Contributions totalling £nil were payable to the fund at the reporting date and are included in creditors. 


11.


Related party transactions

The company is exempt from disclosing related party transactions undertaken with other wholly owned members of the group that have been concluded under normal market conditions.


12.


Post balance sheet events

There have been no significant events affecting the Company since the period end.


13.


Controlling party

The immediate parent company is Aurobac Therapeutics SAS, a company incorporated in France. Its registered office address is 29 Avenue, Tony Garnier, 690007, Lyon, France. 
The ultimate parent company is C.H. Boehringer Sohn AG & Co. KG, a company incorporated in Germany. Its registered office address is Binger Street, 173-55218, Ingelheim am, Rhein, Rheinland-Pfalz, Germany.
Aurobac Therapeutics SAS, prepares group financial statements where this is entity is included which are not publicly available.

- 6 -

 
 14939347
31 December 2023
AUROBAC THERAPEUTICS UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

14.


Auditor's information

The auditor's report on the financial statements for the period ended 31 December 2023 was unqualified.

The audit report was signed on 2 April 2024 by Sally Casson (Senior statutory auditor) on behalf of Ecovis Wingrave Yeats LLP.

- 7 -